class
envelop
virus
share
similar
appar
use
hexamer
coiledcoil
assembl
drive
merg
viru
host
cell
membran
inhibit
coil
coilmedi
interact
use
bioactiv
peptid
replic
chain
viral
fusion
machineri
signific
antivir
potenti
present
construct
seri
lipopeptid
compos
de
novo
heptad
repeat
sequencebas
peptid
plu
hydrocarbon
tail
promisingli
construct
adopt
stabl
conform
exhibit
rel
broadspectrum
antivir
activ
middl
east
respiratori
syndrom
coronaviru
merscov
influenza
virus
iav
togeth
find
reveal
new
strategi
rel
broadspectrum
antivir
drug
discoveri
reli
tunabl
coiledcoil
domain
present
class
fusion
protein
amphiphil
natur
individu
helic
multihelix
motif
tradit
one
drug
paradigm
develop
antivir
therapeut
yield
laudabl
success
control
emerg
reemerg
threat
viral
pathogen
howev
broadspectrum
antivir
strategi
afford
time
effect
pharmacolog
agent
respond
increas
divers
highli
pathogen
virus
remain
elus
common
viral
life
cycl
ie
fusion
envelop
virus
host
cell
membran
repres
viabl
target
discoveri
broadspectrum
therapeut
fusion
process
trigger
format
leucin
zipperlik
hexam
either
cell
surfac
within
later
endosom
typic
structur
featur
class
fusion
glycoprotein
use
envelop
virus
human
immunodefici
viru
type
influenza
virus
iav
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
ebov
figur
coiledcoil
sixhelix
bundl
assembl
three
ntermin
heptad
repeat
nhr
region
viral
fusion
protein
initi
form
central
trimer
helix
scaffold
becom
temporarili
expos
creat
metast
prehairpin
conform
three
ctermin
heptad
repeat
chr
region
pack
onto
peripheri
trimer
nhr
inner
core
antiparallel
orient
bioactiv
peptid
deriv
chr
motif
class
viral
fusion
protein
design
cpeptid
act
decoy
abl
bind
correspond
nhr
helic
trimer
form
heterolog
nonfunct
structur
virusspecif
manner
therebi
antagon
refold
endogen
chr
region
competit
inhibit
cell
membran
fusion
jiang
colleagu
discov
highli
potent
fusion
inhibitori
peptid
deriv
chr
region
design
wild
et
al
report
anoth
chrpeptid
also
name
later
brand
name
fuzeon
gener
name
enfuvirtid
final
approv
us
food
drug
administr
clinic
use
first
fusion
inhibitorbas
antihiv
drug
discoveri
antihiv
peptid
spur
identif
antivir
peptid
virus
util
class
fusion
protein
includ
recent
identifi
merscov
emerg
merscov
infect
gao
group
jiang
group
independ
solv
crystal
structur
merscov
fusion
core
basi
structur
jiang
group
report
highli
effect
antimerscov
peptid
recent
identifi
hydrocarbonstapl
short
peptid
could
inhibit
merscov
infect
low
micromolar
level
consid
univers
fusion
mechan
employ
class
envelop
virus
inhibit
nhrchr
coil
coilmedi
interact
signific
potenti
develop
broadspectrum
therapeut
intervent
coil
coil
ubiquit
protein
fold
motif
found
natur
orchestr
associ
numer
complex
implic
biolog
process
wealth
structur
inform
provid
rel
detail
understand
sequencetostructur
relationship
supercoil
scaffold
structur
term
amphipath
encod
canon
coil
coil
via
burial
hydrophob
face
drive
multimer
constitu
helic
hexamer
coiledcoil
assembl
present
arguabl
best
character
class
viral
fusion
apparatu
chelic
divid
hydrophob
buri
bind
interfac
hydrophil
solventaccess
site
figur
structur
analysi
demonstr
high
variabl
primari
sequenc
chr
motif
within
allow
long
drive
forc
coiledcoil
assembl
ie
amphiphil
characterist
individu
helic
maintain
accordingli
hivneutr
cpeptid
engin
strategi
salt
bridg
helixfavor
amino
acid
hydrophob
mutat
buri
residu
significantli
enhanc
bundl
stabil
compar
correspond
wildtyp
ligand
despit
substitut
approxim
half
parent
residu
incorpor
alkyl
hydrocarbon
tail
onto
peptid
repres
anoth
promis
techniqu
recent
studi
fusion
inhibitor
reveal
lipidconjug
cpeptid
greatli
increas
nhrbind
capabl
moreov
virus
fuse
cell
surfac
lipid
also
provid
critic
advantag
endow
cpeptid
membranetrop
featur
enrich
local
concentr
helic
peptid
membran
level
facilit
assembl
intermediatestag
nhrhelic
trimer
intracellularli
fuse
virus
lipid
allow
antivir
peptid
intern
along
virus
host
cell
therebi
arrest
format
endosom
take
advantag
adjust
tractabl
interact
core
structur
typic
class
viral
fusion
protein
herein
describ
ration
approach
design
rel
broadspectrum
inhibitor
infect
merscov
famili
coronavirida
primarili
employ
cell
surfac
pathway
iav
famili
orthomyxovirida
use
endocyt
rout
base
replic
topographi
chr
helic
use
de
novo
design
amphiphil
peptid
addit
fatti
acid
tail
term
sequenc
coiledcoil
domain
share
characterist
heptad
repeat
usual
denot
abcdefg
hydrophob
residu
core
ad
posit
hydrophil
residu
site
helix
wheel
model
nhrchr
structur
residu
ade
site
chelic
face
inner
nhelic
larg
buri
residu
primarili
respons
interact
meanwhil
residu
bcfg
site
locat
away
interact
center
therefor
adopt
heptad
repeat
approach
design
amphiphil
peptid
base
sequenc
ac
x
e
b
e
c
x
z
e
k
f
k
g
nh
repeat
heptapeptid
sequenc
place
hydrophob
residu
x
posit
polar
charg
residu
z
posit
foreground
ad
e
posit
model
sequenc
set
background
bcfg
site
popul
combin
glutam
acid
lysin
form
doubl
gluli
intrastrand
salt
bridg
articl
posit
favor
overal
solubl
heptad
repeat
peptid
semin
work
investig
structur
character
coil
coil
suggest
stabil
helic
bundl
directli
proport
number
heptad
repeat
combin
optim
peptid
length
paradigm
establish
current
peptid
fusion
inhibitor
design
sequenc
made
five
heptad
ie
residu
addit
append
outsid
heptad
repeat
region
order
link
extra
lysin
residu
cap
palmitoyl
group
thu
provid
membranetrop
featur
favor
safeti
profil
drug
develop
figur
initi
aim
establish
combin
foreground
ad
residu
heptad
repeat
moieti
previou
experi
indic
alanin
residu
strongli
bias
toward
helix
format
peptid
design
novel
lipopeptid
began
peptid
name
aa
tabl
hydrophob
alanin
residu
place
posit
heptad
small
helixfavor
polar
residu
ie
serin
wide
util
protein
function
scan
strategi
popul
e
posit
explor
influenc
hydrophob
residu
contact
coiledcoil
interact
site
antivir
activ
substitut
ad
posit
peptid
aa
made
differ
hydrophob
residu
includ
val
phe
tyr
leu
ile
use
previous
develop
merscov
proteinmedi
fusion
assay
test
biolog
activ
peptid
shown
tabl
lipopeptid
potent
inhibit
fusion
mediat
merscov
protein
effect
concentr
ec
valu
rang
six
lipopeptid
design
ll
ii
found
potent
merscov
fusion
inhibitor
ec
valu
respect
possibl
reason
activ
includ
evolutionari
prefer
leu
ile
heptad
posit
ad
viral
fusion
glycoprotein
sequenc
signific
creat
enough
hydrophobicityamphiphil
yield
stabl
coiledcoil
structur
compar
ll
ii
possess
obvious
lower
cytotox
cell
use
target
cell
fusion
assay
therefor
next
round
analogu
mutat
residu
e
posit
heptad
ii
differ
type
polar
residu
includ
cation
ly
anion
glu
uncharg
gln
well
aromaticheterocycl
amino
acid
tyr
trp
expect
optim
would
provid
improv
potenc
cytotox
strikingli
glncontain
iiq
tyrcontain
iiy
ec
valu
respect
even
reach
potenc
merscovspecif
fusion
inhibitor
peptid
addit
iiq
iiy
possess
lower
cytotox
valu
select
lead
ii
cytotox
concentr
cc
valu
subsequ
test
inhibitori
activ
peptid
iiq
entri
pseudoviru
carri
wildtyp
merscov
protein
shown
support
inform
figur
iiq
effect
merscov
pseudoviru
infect
ec
valu
find
close
agreement
cell
fusion
assay
result
data
impli
de
novo
design
peptid
nonhomolog
natur
occur
merscov
protein
sequenc
could
effect
inhibit
merscov
infect
target
cell
membran
fusion
moreov
explor
structur
properti
lipopeptid
circular
dichroism
cd
spectroscopi
determin
propens
adopt
structur
correl
antimerscov
activ
relationship
ec
lipopeptid
content
shown
figur
support
inform
found
potenc
strictli
depend
r
suggest
factor
solubl
target
bind
affin
kinet
may
involv
biolog
activ
phenomena
also
observ
studi
fusion
inhibitor
sever
cpeptid
exhibit
potenc
despit
fulli
structur
solut
number
cell
fuse
unfus
cell
counter
percentag
inhibit
calcul
describ
experiment
section
data
deriv
result
three
independ
experi
express
mean
standard
deviat
b
peptid
acetyl
group
nterminu
carboxyamid
cterminu
letter
ag
indic
posit
correspond
residu
helic
wheel
present
c
cytotox
cell
ongo
threat
emerg
resist
variant
diminish
ablat
effect
current
avail
antiiav
drug
underscor
demand
new
antivir
strategi
target
protein
influenza
viru
life
cycl
therefor
employ
cytopath
effect
inhibit
assay
evalu
inhibit
effect
compound
ii
iiy
iiq
exhibit
promis
potenc
inhibit
merscov
infect
iav
surprisingli
one
lipopeptid
iiq
display
potent
inhibitori
activ
toward
strain
apuerto
ahong
ec
valu
respect
tabl
furthermor
none
peptid
display
cytotox
effect
canin
kidney
mdck
cell
concentr
select
index
iiq
larger
indic
safe
profil
explor
data
present
tabl
support
inform
show
iiq
also
potent
oseltamivirresist
strain
includ
ec
valu
respect
wherea
oseltamivir
much
less
effect
ec
inact
concentr
addit
iiq
also
exert
remark
inhibitori
activ
strain
infect
ec
valu
expect
merscov
display
inhibit
effect
apuerto
hong
infect
concentr
life
cycl
influenza
viru
divid
three
step
ie
viru
entri
viral
genom
replic
progeni
virion
releas
current
sever
antiinfluenza
drug
develop
interrupt
specif
process
influenza
infect
among
oseltamivir
tamiflu
target
neuraminidas
na
protein
thu
prevent
releas
tether
progeni
viru
host
cell
favipiravir
select
inhibit
rnadepend
rna
polymeras
approv
japan
inhibitor
influenza
viru
replic
treatment
influenza
viru
infect
ask
iiq
peptid
act
inhibit
entri
step
iav
host
cell
address
question
viral
replicon
assay
neuraminidas
inhibit
assay
perform
articl
rule
effect
iiq
viral
replic
progeni
virion
releas
respect
minireplicon
system
viral
rna
polymeras
protein
express
plasmid
mediat
express
report
genom
encod
firefli
luciferas
determin
normal
firefli
luminescencerenilla
luminesc
ratio
found
favipiravir
could
inhibit
influenza
replicon
activ
dosedepend
manner
inhibitori
concentr
ic
valu
wherea
iiq
neuraminidas
inhibitor
oseltamivir
exhibit
signific
inhibit
concentr
figur
shown
figur
c
neither
iiq
favipiravir
abl
disturb
cleavag
substrat
neuraminidas
two
iav
strain
apuerto
ahong
test
rang
contrast
oseltamivir
could
inhibit
neuraminidas
two
virus
ic
valu
nm
respect
taken
togeth
result
suggest
iiq
may
affect
entri
stage
viral
life
cycl
block
viru
infect
moreov
use
timeofaddit
assay
found
viral
load
interv
h
cover
whole
life
cycl
h
cover
entri
step
reduc
approxim
addit
iiq
compar
pb
control
antivir
activ
observ
remain
three
time
interv
h
howev
favipiravir
continu
exert
full
effect
even
interv
h
result
confirm
iiq
target
entri
step
iav
life
cycl
figur
hemagglutin
inhibit
hi
assay
wellestablish
determin
whether
sialic
acidbind
site
subunit
act
potenti
drug
target
meanwhil
hemolysi
inhibit
assay
commonli
use
determin
whether
subunit
possibl
target
thu
hi
assay
first
perform
determin
potenti
effect
iiq
peptid
subunit
sialic
acidbind
site
result
show
appar
inhibit
influenza
virusinduc
aggreg
chicken
erythrocyt
observ
test
rang
indic
iiq
effect
interact
subunit
sialic
acid
receptor
support
inform
figur
moreov
hemolysi
inhibit
assay
show
lysi
erythrocyt
caus
conform
rearrang
subunit
acid
condit
decreas
compar
hemolyt
effect
viru
support
inform
figur
combin
result
indic
iiq
may
bind
subunit
interrupt
conform
chang
rather
articl
interact
subunit
via
inhibit
absorpt
virus
host
cell
consist
design
rational
identifi
entryfus
process
phase
life
cycl
merscov
iav
point
interfer
explor
whether
iiq
peptid
would
interact
correspond
nhr
region
viral
fusion
protein
mechan
action
similar
virusspecif
cpeptid
first
piec
evid
came
nativ
polyacrylamid
gel
electrophoresi
npage
equimolar
mixtur
iiq
plu
synthet
peptid
contain
nhr
segment
merscov
spike
protein
subunit
design
postfus
structur
hemagglutinin
ha
subunit
name
respect
mixtur
show
new
band
upper
posit
gel
demonstr
tightli
associ
complex
form
figur
find
consist
result
obtain
circular
dichroism
cd
spectroscopi
signal
mixtur
dramat
greater
mathemat
sum
correspond
isol
peptid
suggest
induct
larg
structur
result
interact
figur
c
moreov
data
cd
analysi
indic
helic
bundl
show
strong
thermal
stabil
melt
temperatur
valu
respect
figur
support
inform
tabl
cd
analysi
avail
crystal
structur
wide
use
repres
fusion
core
use
posit
control
support
inform
figur
final
sediment
veloc
analysi
demonstr
heterogen
state
complex
complex
support
inform
tabl
figur
togeth
data
suggest
activ
iiq
peptid
inde
associ
site
nhr
region
form
heterogen
structur
interfer
fusion
viru
target
cell
membran
use
larg
unilamellar
vesicl
popc
luv
liposom
system
examin
abil
iiq
interact
lipid
bilay
measur
heat
gener
bind
isotherm
titrat
calorimetri
assay
shown
figur
huge
amount
releas
heat
observ
titrat
popc
luv
solut
contain
iiq
peptid
bind
constant
comparison
unconjug
peptid
exhibit
signific
inhibitori
activ
concentr
merscov
pseudoviru
apuerto
infect
show
lipid
vesicl
bind
observ
indic
iiq
bind
lipid
bilay
although
chr
peptid
provid
classic
paradigm
ration
design
fusion
inhibitor
interfer
interact
heptadrepeat
region
class
viral
fusion
protein
develop
drug
novel
mode
action
iav
remain
challeng
mainli
inaccess
exogen
ad
cpeptid
endocyt
compart
fusogen
format
take
place
thu
next
append
fluoresc
probe
nitrobenzoxadiazol
nbd
nterminu
iiq
via
spacer
gener
iiq
nbd
monitor
cellular
uptak
iiq
nbd
found
similar
iiq
term
inhibitori
potenc
iav
infect
indic
addit
fluorophor
dramat
affect
biophys
biolog
properti
iiq
support
inform
tabl
demonstr
cellular
uptak
mdck
cell
treat
iiq
nbd
observ
incub
h
confoc
microscopi
lysotrack
probe
specif
fluoresc
acid
vesicl
shown
figur
mdck
cell
expos
iiq
nbd
h
show
lipopeptid
distribut
peripheri
cell
membran
h
accumul
iiq
nbd
within
mdck
cell
detect
acid
intracellular
compart
coloc
articl
lysotrack
red
moreov
h
increas
amount
iiq
nbd
intern
coloc
extens
lysotrack
red
taken
togeth
result
suggest
lipopeptid
could
cross
plasma
membran
effici
via
endocytosi
trap
iav
fusion
protein
prehairpin
intermedi
state
therebi
block
membran
fusion
subsequ
iiq
peptid
assess
essenti
druglik
properti
includ
water
solubl
vivo
pharmacokinet
properti
iiq
show
solubl
valu
mg
ml
pure
water
pharmacokinet
behavior
iiq
evalu
rat
figur
tabl
rat
inject
intraven
mgkg
iiq
peptid
blood
withdrawn
min
min
min
min
h
h
h
h
h
h
respect
three
anim
time
point
lcmsm
method
show
satisfactori
result
determin
iiq
rat
plasma
use
pharmacokinet
studi
inspect
plasma
profil
iiq
reveal
mean
valu
maximum
plasma
concentr
c
max
obtain
min
dose
area
plasma
curv
extrapol
last
time
point
auc
elimin
kinet
iiq
demonstr
durabl
plasma
halflif
h
concentr
iiq
plasma
remain
well
limit
quantit
analyt
method
h
furthermor
iiq
peptid
low
rate
clearanc
togeth
favor
pharmacokinet
iiq
includ
efficaci
exposur
level
low
clearanc
rel
extend
halflif
vivo
suggest
iiq
suitabl
studi
drug
candid
investig
whether
engin
lipopeptid
exert
broad
antivir
spectrum
beyond
coronavirida
orthomyxovirida
famili
iiq
peptid
evalu
envelop
glycoprotein
env
mediat
fusion
ebola
viru
ebov
envelop
glycoprotein
gp
mediat
cell
entri
found
iiq
inhibit
envmedi
cell
fusion
ec
exhibit
low
cytotox
cc
cell
use
fusion
assay
encouragingli
iiq
also
inhibit
entri
pseudoviru
carri
gp
ebov
sudan
speci
ec
valu
knowledg
format
hexamer
coiledcoil
complex
believ
common
element
type
fusion
event
howev
fusion
rate
vari
significantli
virus
differ
famili
virus
within
famili
even
isol
speci
thu
lead
differ
window
period
inhibitori
peptid
access
target
fusion
protein
therebi
impact
entri
inhibitor
efficaci
furthermor
stabil
correspond
fusogen
differ
type
viral
fusion
protein
also
correl
inhibitori
potenc
peptid
therefor
engin
lipopeptid
simpl
repeat
unit
heptad
studi
could
effect
class
virus
entri
first
provid
proofofconcept
prototyp
broadspectrum
antivir
agent
design
moreov
lipopeptid
may
also
use
lead
compound
optim
design
inhibitor
broader
antivir
spectrum
basi
common
featur
fusogen
structur
form
chr
nhr
region
class
viral
fusion
glycoprotein
report
effect
strategi
expedit
develop
rel
broadspectrum
antivir
drug
studi
reveal
de
novo
design
lipopeptid
nonhomolog
natur
occur
protein
sequenc
interact
merscov
iav
nhr
trimer
coil
coil
prevent
membran
fusion
one
design
peptid
show
high
potenc
merscov
infect
effect
neutral
apuerto
influenza
group
articl
ahong
influenza
group
even
influenza
b
viru
rel
broadspectrum
antivir
peptid
design
base
secondari
structur
hexamer
coiledcoil
complex
interfac
anticip
approach
could
also
extend
pathogen
virus
class
fusion
protein
undergo
fusion
catalysi
manner
similar
merscov
iav
reactor
reaction
stir
room
temperatur
min
complet
coupl
reaction
fmoc
remov
resin
wash
dmf
min
dcm
min
lipopeptid
templat
peptid
contain
ddeprotect
lysin
residu
cterminu
requir
special
deprotect
step
four
min
wash
hydrazinehydr
dmf
enabl
conjug
palmityl
moieti
perform
addit
equiv
palmic
acid
equiv
hbtu
equiv
diea
dmf
resin
follow
stir
h
conjug
fluorid
nbd
fluoresc
probe
nterminu
peptid
perform
addit
equiv
nbdcl
dissolv
dmf
togeth
equiv
diea
peptid
resin
follow
stir
h
peptid
cleav
resin
deprotect
reagent
k
contain
trifluoroacet
acid
thioanisol
mcresol
water
carboxyl
termini
amid
upon
cleavag
resin
amino
termini
cap
acet
acid
anhydrid
except
nbdconjug
peptid
lyophil
crude
peptid
purifi
reversedphas
highperform
liquid
chromatographi
rphplc
shimadzu
prepar
hplc
system
puriti
peptid
confirm
analyt
rphplc
shimadzu
analyt
hplc
system
inform
provid
support
inform
tabl
inhibit
pseudotyp
merscov
infect
inhibit
merscov
pseudoviru
infect
assess
use
previous
describ
method
briefli
serial
dilut
test
peptid
ad
plate
incub
merscov
pseudoviru
min
pseudoviruspeptid
mixtur
ad
cell
cultur
refe
fresh
medium
h
postinfect
incub
addit
h
fluoresc
determin
use
luciferas
kit
promega
ultra
luminomet
tecan
cytopath
effect
reduct
assay
canin
kidney
mdck
cell
seed
plate
nunc
microwel
densiti
cellswel
dulbecco
modifi
eagl
mediumham
medium
incub
overnight
adher
plate
dilut
seri
test
compound
tosylsulfonyl
phenylalanyl
chloromethyl
keton
tpck
trypsin
ad
cell
infect
influenza
viru
apuerto
ahong
final
multipl
infect
moi
pfucel
suspend
medium
tpcktrypsin
incub
h
antivir
effect
test
compound
measur
use
celltiterglo
cell
viabil
assay
promega
usa
describ
manufactur
plate
read
spectramax
micropl
reader
molecular
devic
usa
cytotox
assay
cytotox
compound
cell
briefli
cell
suspens
cellsml
ad
well
cultur
plate
plate
incub
co
h
next
serial
dilut
peptid
solut
ad
time
blank
control
group
without
peptid
posit
control
group
triton
cultur
h
condit
co
well
ad
cell
count
kit
solut
plate
incub
addit
h
absorb
nm
determin
micropl
reader
cytotox
compound
mdck
cell
mdck
cell
seed
plate
densiti
cellswel
medium
incub
overnight
dilut
seri
test
compound
medium
tpcktrypsin
ad
cell
h
treatment
cytotox
measur
celltiterglo
cell
viabil
assay
promega
usa
cytotox
concentr
data
fit
determin
origin
softwar
influenza
viru
replic
assay
human
embryon
kidney
cell
seed
plate
nunc
microwel
densiti
cellswel
medium
incub
overnight
plasmid
encod
influenza
replic
complex
compon
np
pa
encod
luciferas
report
polinsluc
prl
transfect
cell
use
lipofectamin
invitrogen
usa
h
posttransfect
serial
dilut
oseltamivir
favipiravir
iiq
ad
indic
concentr
h
luciferas
activ
measur
use
spectramax
micropl
reader
molecular
devic
usa
dualglo
luciferas
assay
kit
promega
usa
accord
standard
protocol
replicon
activ
repres
ratio
firefli
luciferas
activ
rel
renilla
articl
luciferas
activ
replicon
activ
inhibit
test
compound
calcul
use
follow
formula
inhibit
replicon
activ
experiment
sampl
ratio
neg
control
ratio
posit
control
ratio
neg
control
ratio
curv
fit
perform
origin
softwar
neuraminidas
inhibit
assay
nastar
influenza
neuraminidas
inhibitor
resist
detect
kit
appli
biosystem
usa
use
measur
inhibit
neuraminidas
activ
accord
manufactur
instruct
neuraminidas
influenza
ahong
neuraminidas
influenza
apuerto
viru
use
assay
chemiluminesc
signal
intens
assay
plate
measur
immedi
acceler
inject
read
time
set
inhibitori
activ
oseltamivir
favipiravir
iiq
calcul
use
follow
formula
inhibitori
activ
harvest
appli
qpcr
viral
load
analysi
cell
continu
cultur
fresh
medium
remov
test
compound
h
postinfect
viral
load
analyz
total
rna
cell
sampl
extract
use
rneasi
mini
kit
qiagen
absolut
rtqpcr
perform
use
abi
step
one
plu
platform
use
onestep
primescript
rtpcr
kit
takara
sampl
run
triplic
detail
primer
probe
sequenc
reaction
system
found
support
inform
mrna
express
profil
differ
time
interv
iiq
favipiravir
pb
treatment
analyz
mrna
express
profil
iiq
favipiravir
treatment
present
rel
pb
control
statist
signific
data
determin
manova
method
use
spss
softwar
circular
dichroism
cd
spectroscopi
cd
spectra
acquir
system
biolog
claix
franc
follow
paramet
bandwidth
nm
resolut
nm
path
length
cm
respons
time
scan
speed
nmmin
incub
iiq
min
mm
phosphat
buffer
ph
incub
iiq
min
mm
sodium
acet
buffer
contain
mm
sodium
phosphat
mm
sodium
chlorid
ph
sampl
prepar
buffer
solut
final
concentr
cool
measur
cd
data
present
mean
residu
ellipt
content
peptid
calcul
assum
helic
correspond
degre
cm
dmol
thermal
unfold
experi
cd
absorb
monitor
nm
temperatur
peptid
solut
rang
scan
speed
sampl
ph
contain
peptid
mm
sodium
acet
buffer
contain
mm
sodium
phosphat
mm
sodium
chlorid
sampl
ph
contain
peptid
mm
phosphat
buffer
nativ
polyacrylamid
gel
electrophoresi
equimolar
mixtur
iiq
mm
phosphat
buffer
ph
incub
min
final
concentr
peptid
addit
acid
nativ
sampl
buffer
sampl
ratio
sampl
load
acid
gel
acid
run
buffer
ph
sampl
load
sampl
concentr
constant
voltag
v
sampl
reach
boundari
two
gel
voltag
rais
v
sampl
electrophores
h
indic
within
cm
lead
edg
gel
subsequ
stain
coomassi
blue
equimolar
mixtur
iiq
mm
sodium
acet
buffer
contain
mm
sodium
phosphat
mm
sodium
chlorid
ph
incub
min
final
concentr
peptid
incub
solut
equilibr
room
temperatur
ph
neutral
addit
mm
tri
buffer
ph
addit
trisglycin
nativ
sampl
buffer
invitrogen
usa
sampl
ratio
sampl
load
onto
trisglycin
gel
run
buffer
ph
sampl
load
sampl
concentr
constant
voltag
v
sampl
reach
boundari
two
gel
voltag
rais
v
sampl
electrophores
h
indic
within
cm
lead
edg
gel
subsequ
stain
coomassi
blue
sediment
veloc
analysi
sva
beckman
xlatyp
ultracentrifug
use
sva
experi
incub
iiq
min
mm
phosphat
buffer
ph
incub
iiq
min
mm
sodium
acet
buffer
contain
mm
phosphat
mm
sodium
chlorid
ph
sampl
prepar
final
concentr
measur
uv
absorpt
experi
data
collect
nm
rotor
speed
rpm
initi
rpm
continu
mode
sediment
coeffici
distribut
c
measur
molecular
weight
distribut
calcul
sedfit
softwar
isotherm
titrat
calorimetri
itc
itc
perform
detect
iiq
lipidbind
activ
describ
previous
solut
degass
vacuum
prior
use
detect
iiq
lipidbind
activ
larg
unilamellar
vesicl
luv
popc
liposom
use
luv
popc
mm
inject
cell
contain
peptid
solut
experi
use
microc
system
ge
alpharetta
ga
usa
titrat
follow
experiment
paramet
total
inject
drop
drop
volum
syring
concentr
mm
cell
concentr
cell
temperatur
energi
refer
titrat
delay
stir
speed
rpm
drop
volum
titrat
time
twodrop
interv
data
collect
interv
data
acquisit
analys
perform
use
origin
softwar
version
microc
immunofluoresc
assay
mdck
cell
pretreat
lysotrack
red
purchas
thermo
fisher
scientif
shanghai
china
lysotrack
solut
mm
ad
ml
growth
medium
obtain
work
solut
nm
cell
plate
incub
nm
lysotrack
work
solut
h
wash
twice
pb
medium
without
phenol
red
contain
iiq
nbd
ad
cell
time
point
h
cell
cultur
co
time
point
min
min
h
h
h
cell
scan
operetta
confoc
imag
system
provid
perkinelm
object
len
follow
filter
use
alexa
fluor
acid
intracellular
compart
fitc
iiq
nbd
pharmacokinet
assess
rat
weigh
g
obtain
anim
center
beij
institut
pharmacolog
toxicolog
use
pharmacokinet
assess
anim
treat
accord
anim
welfar
act
guid
care
use
laboratori
anim
nih
public
revis
complet
pharmacokinet
experiment
procedur
provid
support
inform
support
inform
avail
free
charg
ac
public
websit
doi
articl
inhibitori
activ
compound
oseltamivirresist
strain
biophys
properti
iiq
peptid
summari
sva
result
iiq
complex
biolog
biophys
properti
iiq
nbd
hplc
method
use
purif
peptid
compound
hplc
method
use
analysi
peptid
compound
iiq
peptid
inhibitor
merscov
infect
correl
content
lipopeptid
observ
ec
identif
subunit
potenti
target
iiq
compound
interact
molecular
mass
determin
sva
pharmacokinet
assess
aqueou
solubl
determin
envmedi
fusion
assay
inhibit
pseudotyp
ebola
viru
infect
hemagglutin
inhibit
assay
hemolysi
inhibit
assay
well
malditofm
analyt
hplc
design
peptid
pdf
